Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only introduces drugs related to medical health and does not recommend treatment plans (if involved), nor does it represent the platform's position. Authorization is required for the reprint of any article.According to the drug approval certificate delivery information released by NMPA on December 18, 2023, 31 varieties(40 Specifications)Latest Approval, involvingQilu, Humanwell, Yangtze RiverAnd many other pharmaceutical companies.Among them,10% Fat Emulsion (OO) / 5.5% Amino Acids(15)/Glucose (20%) Injection, Cefixime for SuspensionTwo varietiesThe first one passed the review;Apixaban TabletsThree pharmaceutical companies pass the review on the same day;Vildagliptin TabletsWelcome2HomeMedicineApproved on the Same Day。Yangtze River Pharmaceutical Group Co., Ltd. Secures Over 400 MillionDexrazoxane for InjectionVariety, More passing situations,See the table and mini-program below for details.12.18 Approved Varieties (Marked in Red for the First Approval)
Data Source:PharmCube Approved Drugs Summary Database
Recent Popular Resource AcquisitionReply to the keyword "Report", access dozens of exclusive reports produced by Yaorong Cloud
Reply to the keyword "CSCO", Obtain 2023 CSCO Guidelines
Reply to the keyword "ASCO", Obtain 2023 ASCO Abstract by Cancer Type
Reply to the keyword "First Generic in 2022", obtain the list of first generic drugs approved in 2022
Reply to the keyword "Medical Insurance", Obtain the 2022 Medical Insurance Catalog
Contact us to experience more professional services from PharmaCloud. |
MeetingDiscussion CombinedWork | GardenDistrict TakeWu | Database Consultation | Customization Service | Media Cooperation |
ClickReadRead the Original Text, apply for a free trial of PharmaCube Enterprise Edition!
